Cargando…

Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection

A vaccine to prevent genital herpes is an unmet public health need. We previously reported that a trivalent vaccine containing herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, gD2, gE2) produced in baculovirus and administered with CpG/alum as adjuvants blocks immune evasion media...

Descripción completa

Detalles Bibliográficos
Autores principales: Egan, Kevin, Hook, Lauren M., Naughton, Alexis, Friedman, Harvey M., Awasthi, Sita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553673/
https://www.ncbi.nlm.nih.gov/pubmed/32347775
http://dx.doi.org/10.1080/21645515.2020.1749509
_version_ 1783593653279653888
author Egan, Kevin
Hook, Lauren M.
Naughton, Alexis
Friedman, Harvey M.
Awasthi, Sita
author_facet Egan, Kevin
Hook, Lauren M.
Naughton, Alexis
Friedman, Harvey M.
Awasthi, Sita
author_sort Egan, Kevin
collection PubMed
description A vaccine to prevent genital herpes is an unmet public health need. We previously reported that a trivalent vaccine containing herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, gD2, gE2) produced in baculovirus and administered with CpG/alum as adjuvants blocks immune evasion mediated by gC2 and gE2 and virus entry by gD2. The vaccine protected guinea pigs against HSV-2 vaginal infection. We evaluated whether the HSV-2 vaccine cross-protects against HSV-1 because many first-time genital herpes infections are now caused by HSV-1. Guinea pigs were mock immunized or immunized with the trivalent vaccine and challenged intravaginally with a different HSV-1 isolate in two experiments. Guinea pigs immunized with the trivalent vaccine developed genital lesions on fewer days than the mock group: 2/477 (0.4%) days compared to 15/424 (3.5%) in experiment one, and 0/135 days compared to 17/135 (12.6%) in experiment two (both P < .001). No animal in the trivalent group had HSV-2 DNA detected in vaginal secretions: 0/180 days for trivalent compared to 4/160 (2.5%) for mock (P < .05) in experiment one, and 0/65 days for trivalent compared to 4/65 (6%) for mock in experiment two. Therefore, a vaccine designed to prevent HSV-2 also protects against HSV-1 genital infection.
format Online
Article
Text
id pubmed-7553673
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75536732020-10-23 Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection Egan, Kevin Hook, Lauren M. Naughton, Alexis Friedman, Harvey M. Awasthi, Sita Hum Vaccin Immunother Short Report A vaccine to prevent genital herpes is an unmet public health need. We previously reported that a trivalent vaccine containing herpes simplex virus type 2 (HSV-2) glycoproteins C, D, and E (gC2, gD2, gE2) produced in baculovirus and administered with CpG/alum as adjuvants blocks immune evasion mediated by gC2 and gE2 and virus entry by gD2. The vaccine protected guinea pigs against HSV-2 vaginal infection. We evaluated whether the HSV-2 vaccine cross-protects against HSV-1 because many first-time genital herpes infections are now caused by HSV-1. Guinea pigs were mock immunized or immunized with the trivalent vaccine and challenged intravaginally with a different HSV-1 isolate in two experiments. Guinea pigs immunized with the trivalent vaccine developed genital lesions on fewer days than the mock group: 2/477 (0.4%) days compared to 15/424 (3.5%) in experiment one, and 0/135 days compared to 17/135 (12.6%) in experiment two (both P < .001). No animal in the trivalent group had HSV-2 DNA detected in vaginal secretions: 0/180 days for trivalent compared to 4/160 (2.5%) for mock (P < .05) in experiment one, and 0/65 days for trivalent compared to 4/65 (6%) for mock in experiment two. Therefore, a vaccine designed to prevent HSV-2 also protects against HSV-1 genital infection. Taylor & Francis 2020-04-29 /pmc/articles/PMC7553673/ /pubmed/32347775 http://dx.doi.org/10.1080/21645515.2020.1749509 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Short Report
Egan, Kevin
Hook, Lauren M.
Naughton, Alexis
Friedman, Harvey M.
Awasthi, Sita
Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
title Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
title_full Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
title_fullStr Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
title_full_unstemmed Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
title_short Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
title_sort herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins c, d and e protects guinea pigs against hsv-1 genital infection
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553673/
https://www.ncbi.nlm.nih.gov/pubmed/32347775
http://dx.doi.org/10.1080/21645515.2020.1749509
work_keys_str_mv AT egankevin herpessimplexvirustype2trivalentproteinvaccinecontainingglycoproteinscdandeprotectsguineapigsagainsthsv1genitalinfection
AT hooklaurenm herpessimplexvirustype2trivalentproteinvaccinecontainingglycoproteinscdandeprotectsguineapigsagainsthsv1genitalinfection
AT naughtonalexis herpessimplexvirustype2trivalentproteinvaccinecontainingglycoproteinscdandeprotectsguineapigsagainsthsv1genitalinfection
AT friedmanharveym herpessimplexvirustype2trivalentproteinvaccinecontainingglycoproteinscdandeprotectsguineapigsagainsthsv1genitalinfection
AT awasthisita herpessimplexvirustype2trivalentproteinvaccinecontainingglycoproteinscdandeprotectsguineapigsagainsthsv1genitalinfection